* Surmodics Inc SRDX.OQ SRDX.O is expected to show a
rise in
quarterly revenue when it reports results on August 2.
* The Eden Prairie Minnesota-based company is expected to
report
a 53.2% increase in revenue to $38.065 million from $24.85
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Surmodics Inc is
for
earnings of 5 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Surmodics
Inc is
$54, above its last closing price of $32.12.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.49 -0.51 -0.40 Beat 21.3
Dec. 31 2023 -0.65 -0.66 -0.50 Beat 23.8
Sep. 30 2022 -0.45 -0.45 -0.26 Beat 42.4
Jun. 30 2022 -0.38 -0.38 -0.34 Beat 11.3
Mar. -0.35 -0.34 -0.22 Beat 35.3
31 2022
Dec. 31 2021 -0.31 -0.31 -0.13 Beat 58.5
Sep. 30 2021 -0.25 -0.25 -0.10 Beat 60
Jun. 30 2021 -0.15 -0.17 -0.17 Met -2
This summary was machine generated July 31 at 18:33 GMT. All
figures in US dollars unless otherwise stated